{"schema_version":"secwatch.filing_event.v1","accession":"0001485003-23-000031","form_type":"8-K","ticker":"CARM","cik":"0001485003","company_name":"Carisma Therapeutics Inc.","filed_at":"2023-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.197905+00:00","generated_at":"2026-06-19T22:49:23.888396+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Sesen Bio merger partner Carisma appoints Moderna CSO Lin Guey to SAB; merger on track for Q1 2023","bullets":["Carisma Therapeutics appointed Lin Guey, PhD (Chief Scientific Officer of Moderna's External Research Ventures) to its Scientific Advisory Board.","Dr. Guey oversees Moderna's partnership with Carisma to develop in vivo engineered CAR-M therapies for cancer.","Merger between Sesen Bio and Carisma expected to close in Q1 2023, subject to stockholder approval and other conditions.","Carisma expects additional preclinical proof-of-concept data for its CAR-M therapy in Q1 2023.","Moderna will fully fund R&D for up to 12 oncology targets under its collaboration with Carisma."],"urls":{"canonical":"https://secwatch.observer/filing/0001485003-23-000031","json":"https://secwatch.observer/filing/0001485003-23-000031.json","markdown":"https://secwatch.observer/filing/0001485003-23-000031.md","text":"https://secwatch.observer/filing/0001485003-23-000031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1485003/000148500323000031/0001485003-23-000031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1485003/000148500323000031/sesn-20230207.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T22:49:23.888396+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}